|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge显示文摘While the incidence of gastric cancer has decreased worldwide in recent decades,the incidence of signetring cell carcinoma(SRCC) is rising. SRCC has a specific epidemiology and oncogenesis and has two forms: early gastric cancer,which can be resected endoscopically in some cases and which has a better outcome than non-SRCC,and advanced gastric cancer,which is generally thought to have a worse prognosis and lower chemosensitivity than non-SRCC. However,the prognosis of SRCC and its chemosensitivity with specific regimens are still controversial as SRCC is not specifically identified in most studies and its poor prognosis may be due to its more advanced stage. It therefore remains unclear if a specific therapeutic strategy is justified,as the benefit of perioperative chemotherapy and the value of taxanebased chemotherapy are unclear. In this review we analyze recent data on the epidemiology,oncogenesis,prognosis and specific therapeutic strategies in both early and advanced SRCC of the stomach and in hereditary diffuse gastric cancer. | Simon Pernot Thibault Voron Geraldine Perkins Christine Lagorce-Pages Anne Berger Julien Taieb | 2015 | World Journal of Gastroenterology2015，21，40： | 30 |
| 2 | Colorectal cancer and immunity:what we know and perspectives显示文摘Strong evidence supports the concept of immunosurveillance and immunoediting in colorectal cancer.In particular,the density of T CD8+and CD45+lymphocyte infiltration was recently shown to have a better prognostic value than the classic tumor node metastasis classification factor.Other immune subsets,as macrophages,natural killer cells or unconventionnal lymphocytes,seem to play an important role.Induction of regulatory T cells(Tregs)or immunosuppressive molecules such as PD-1 or CTLA-4 and downregulation of antigen-presenting molecules are major escape mechanisms to antitumor immune response.The development of these mechanisms is a major obstacle to the establishment of an effective immune response,but also to the use of immunotherapy.Although im-munotherapy is not yet routinely used in colorectal cancer,we now know that most treatments used(chemotherapy and biotherapy)have immunomodulatory effects,such as induction of immunogenic cell death by chemotherapy,inhibition of immunosuppression by antiangiogenic agents,and antibody-dependent cytotoxicity induced by cetuximab.Finally,many immunotherapy strategies are being developed and tested in phaseⅠtoⅢclinical trials.The most promising strategies are boosting the immune system with cytokines,inhibition of immunoregulatory checkpoints,vaccination with vectorized antigens,and adoptive cell therapy.Comprehension of antitumor immune response and combination of the different approaches of immunotherapy may allow the use of effective immunotherapy for treatment of colorectal cancer in the near future. | Simon Pernot Magali Terme Thibault Voron Orianne Colussi Elie Marcheteau Eric Tartour Julien Taieb | 2014 | World Journal of Gastroenterology2014，20，14： | 19 |
| 3 | 化粪池内部流态数值模拟与结构优化探讨显示文摘针对既有建筑的化粪池技术改造和性能提升问题,应用FLUENT软件对传统化粪池三维流场进行了数值模拟计算,并深入分析了传统化粪池内部流态特征,在此基础上,对传统化粪池的结构提出了改进建议。软件数值模拟的结果显示,改进后的化粪池内部流态得到一定程度的优化,有利于化粪池处理效果的提升。 | 吴珊 唐世文 赵锂 赵昕 Simon Thibault | 2013 | 给水排水2013，39，5： | 2 |
| 4 | Numerical analysis of the optimal length and profile of a linearly chirped fiber Bragg grating for dispersion compensation显示文摘 | Simon Thibault Jocelyn Lauzon Jean-Francois Cliché | 1995 | Optics Letters1995，20，： | 1 |
| 5 | Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer显示文摘AIM:To investigate second-line chemotherapy in gemcitabine-pretreated patients with advanced or metastatic pancreatic cancer [(frequency,response,outcome,course of carbohydrate antigen 19-9 (CA 19-9)].METHODS:This retrospective study included all patients with advanced or metastatic pancreatic cancer (adenocarcinoma or carcinoma) treated with secondline chemotherapy in our center between 2000 and 2008.All patients received first-line chemotherapy with gemcitabine,and prior surgery or radiotherapy was permitted.We analyzed each chemotherapy protocol for second-line treatment,the number of cycles and the type of combination used.The primary endpoint was overall survival.Secondary endpoints included progression-free survival,response rate,grade 3-4 toxicity,dosage modifications and CA 19-9 course.RESULTS:A total of eighty patients (38%) underwenta second-line therapy among 206 patients who had initially received first-line treatment with a gemcitabine-based regimen.Median number of cycles was 4 (range:1-12) and the median duration of treatment was 2.6 mo (range:0.3-7.4).The overall disease control rate was 40.0%.The median overall survival and progression-free survival from the start of second-line therapy were 5.8 (95% CI:4.1-6.6) and 3.4 mo (95% CI:2.4-4.2),respectively.Toxicity was generally acceptable.Median overall survival of patients with a CA 19-9 level declining by more than 20% was 10.3 mo (95% CI:4.5-11.6) vs 5.2 mo (95% CI:4.0-6.4) for others (P=0.008).CONCLUSION:A large proportion of patients could benefit from second-line therapy,and CA 19-9 allows efficient treatment monitoring both in first and secondline chemotherapy. | Romain Altwegg Marc Ychou Vanessa Guillaumon Simon Thezenas Pierre Senesse Nicolas Flori Thibault Mazard Ludovic Caillo Stéphanie Faure Emmanuelle Samalin Eric Assenat | 2012 | World Journal of Gastroenterology2012，18，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员